FATE Stock Forecast 2025-2026
Distance to FATE Price Targets
FATE Price Momentum
10 Quality Stocks Worth Considering Now
Researching Fate Therapeutics (FATE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on FATE and similar high-potential opportunities.
Latest FATE Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, FATE has a neutral consensus with a median price target of $5.00 (ranging from $2.50 to $12.00). The overall analyst rating is Buy (7.1/10). Currently trading at $1.11, the median forecast implies a 350.5% upside. This outlook is supported by 5 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Tenthoff at Piper Sandler, projecting a 981.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FATE Analyst Ratings
FATE Price Target Range
Latest FATE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FATE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2025 | Wedbush | David Nierengarten | Neutral | Reiterates | $5.00 |
| Mar 6, 2025 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $4.00 |
| Mar 6, 2025 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| Mar 6, 2025 | Stifel | Benjamin Burnett | Hold | Maintains | $3.00 |
| Nov 19, 2024 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| Nov 13, 2024 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $5.00 |
| Aug 14, 2024 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| Jun 17, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Upgrade | $6.00 |
| May 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Maintains | $5.00 |
| May 10, 2024 | Piper Sandler | Edward Tenthoff | Neutral | Maintains | $4.00 |
| May 10, 2024 | Wedbush | David Nierengarten | Neutral | Maintains | $5.00 |
| May 10, 2024 | BMO Capital | Etzer Darout | Market Perform | Maintains | $6.00 |
| May 10, 2024 | Canaccord Genuity | Bill Maughan | Buy | Maintains | $9.00 |
| May 6, 2024 | Wedbush | David Nierengarten | Neutral | Reiterates | $7.00 |
| Apr 23, 2024 | Wedbush | David Nierengarten | Neutral | Reiterates | $7.00 |
| Apr 11, 2024 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| Mar 28, 2024 | B of A Securities | Tazeen Ahmad | Underperform | Maintains | $6.00 |
| Mar 19, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $7.00 |
| Feb 27, 2024 | Wedbush | David Nierengarten | Neutral | Maintains | $7.00 |
Fate Therapeutics Inc. (FATE) Competitors
The following stocks are similar to Fate Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fate Therapeutics Inc. (FATE) Financial Data
Fate Therapeutics Inc. has a market capitalization of $127.20M with a P/E ratio of -0.7x. The company generates $13.63M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +11.0% quarter-over-quarter, while maintaining an operating margin of -2,527.5% and return on equity of -54.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Fate Therapeutics Inc. (FATE) Business Model
About Fate Therapeutics Inc.
Develops programmed cellular immunotherapies for cancer.
The company creates off-the-shelf cellular therapy candidates using pluripotent stem cells and proprietary technology. It generates revenue by advancing its product pipeline through collaborations with industry leaders and research institutions, aiming to provide innovative therapies for cancer and immune disorders.
Founded in the early 2000s and based in San Diego, Fate Therapeutics is a key innovator in the biotechnology sector, focusing on scalable cell-based therapies that could change treatment paradigms in oncology and immunology. The company addresses significant unmet medical needs, positioning itself to impact patients globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
181
CEO
Dr. Bahram Valamehr M.B.A., Ph.D.
Country
United States
IPO Year
2013
Website
www.fatetherapeutics.comFate Therapeutics Inc. (FATE) Latest News & Analysis
Off-the-shelf CAR T-cell therapy shows promise in meeting unmet medical needs, facilitating enhanced communication with the FDA during development.
The recognition of off-the-shelf CAR T-cell therapy signals potential market growth and regulatory support, which could enhance company valuations and attract investor interest in biotech stocks.
The FDA has granted FATE a Regenerative Medicine Advanced Therapy designation for its candidate FT819, aimed at treating moderate-to-severe systemic lupus erythematosus.
The FDA's designation can accelerate FT819's development and approval process, potentially boosting FATE's market position and investor confidence in future revenue growth.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
16 days agoFate Therapeutics granted 32,200 restricted stock units to two new non-executive employees, vesting over four years, as part of its inducement plan.
Fate Therapeutics' RSU grants signal confidence in new hires and commitment to growth. This can enhance talent retention, potentially boosting innovation and stock value long-term.
FATE Therapeutics reported improved Q4 revenues and losses year over year, highlighting the potential of its innovative pipeline.
FATE Therapeutics' improved Q4 results and promising pipeline indicate potential for growth, which could enhance investor confidence and impact stock performance positively.
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
1 month agoFT819, an off-the-shelf CAR T-cell therapy, has entered Phase 1 dose expansion testing for moderate-to-severe systemic lupus erythematosus (SLE) using fludarabine-free conditioning.
The initiation of Phase 1 Dose Expansion for FT819 signals progress in CAR T-cell therapy, potentially boosting market confidence and impacting stock valuations in biotech focused on autoimmune diseases.
Fate Therapeutics (FATE) reported a quarterly loss of $0.31 per share, better than the expected loss of $0.44, and an improvement from a loss of $0.45 per share a year earlier.
Fate Therapeutics beat earnings estimates, indicating better-than-expected performance and potentially improving investor confidence, which could positively impact stock prices.
Frequently Asked Questions About FATE Stock
What is Fate Therapeutics Inc.'s (FATE) stock forecast for 2025?
Based on our analysis of 26 Wall Street analysts, Fate Therapeutics Inc. (FATE) has a median price target of $5.00. The highest price target is $12.00 and the lowest is $2.50.
Is FATE stock a good investment in 2025?
According to current analyst ratings, FATE has 5 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.11. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FATE stock?
Wall Street analysts predict FATE stock could reach $5.00 in the next 12 months. This represents a 350.5% increase from the current price of $1.11. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fate Therapeutics Inc.'s business model?
The company creates off-the-shelf cellular therapy candidates using pluripotent stem cells and proprietary technology. It generates revenue by advancing its product pipeline through collaborations with industry leaders and research institutions, aiming to provide innovative therapies for cancer and immune disorders.
What is the highest forecasted price for FATE Fate Therapeutics Inc.?
The highest price target for FATE is $12.00 from Edward Tenthoff at Piper Sandler, which represents a 981.1% increase from the current price of $1.11.
What is the lowest forecasted price for FATE Fate Therapeutics Inc.?
The lowest price target for FATE is $2.50 from at , which represents a 125.2% increase from the current price of $1.11.
What is the overall FATE consensus from analysts for Fate Therapeutics Inc.?
The overall analyst consensus for FATE is neutral. Out of 26 Wall Street analysts, 5 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are FATE stock price projections?
Stock price projections, including those for Fate Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.